# United States Patent 8,895,057: Claim Scope, Qsymia Exclusivity, Litigation Risk, and Patent Landscape
US Patent No. 8,895,057 protects a treatment regimen combining controlled-release topiramate with immediate-release phentermine for weight loss. Its principal limitations are the staged dose escalation, defined patient BMI, pharmacokinetic profile, and long-term administration period. The patent is directed to methods of use rather than a broad composition-of-matter claim.
The commercial product most closely associated with the patent is Qsymia, an oral extended-release capsule containing phentermine hydrochloride and topiramate. The patent’s most commercially important claims cover the transition from 3.75 mg/23 mg to either 7.5 mg/46 mg or 15 mg/92 mg of active ingredients, with administration of the maintenance dose for at least two years.
What does US Patent 8,895,057 protect?
US 8,895,057 protects a method of treating overweight or obese patients with an escalating combination of:
| Regimen stage |
Phentermine active |
Topiramate |
Release profile |
Minimum duration |
| First dosage form |
3.75 mg |
23 mg |
Immediate-release phentermine; controlled-release topiramate |
At least 2 weeks |
| Second dosage form under claim 1 |
7.5 mg |
46 mg |
Immediate-release phentermine; controlled-release topiramate |
At least 2 years |
| Second dosage form under claim 18 |
15 mg |
92 mg |
Immediate-release phentermine; controlled-release topiramate |
At least 2 years |
The claims also require:
- A patient with a BMI of at least 25 kg/m².
- Controlled-release topiramate with a Tmax of approximately 6 to 10 hours.
- Lower topiramate Cmax than non-controlled-release topiramate.
- No reduction in total topiramate exposure as measured by AUC.
- Oral administration in dependent claims.
- In some claims, at least 10% body-weight reduction.
- In some claims, obesity-associated conditions such as hypertension, diabetes, elevated fasting glucose, or hypertriglyceridemia.
The patent therefore protects a specific pharmacologic and clinical-use profile. It does not claim every phentermine/topiramate combination, every controlled-release topiramate formulation, or every weight-loss use of the two active ingredients.
How broad are the independent claims?
Claims 1 and 18 are the two independent claims.
Claim 1: intermediate maintenance dose
Claim 1 requires administration of the 3.75 mg/23 mg starting dose followed by the 7.5 mg/46 mg dose. The patient must receive the first dosage form daily for at least two weeks and the second dosage form daily for at least two years.
The claim is narrow because infringement requires the complete sequence. A product or treatment protocol that begins with a different dose, uses a shorter titration period, or does not provide the claimed maintenance period may fall outside the literal wording of the claim.
Claim 18: highest maintenance dose
Claim 18 has a similar structure but requires the second dosage form to contain 15 mg phentermine and 92 mg topiramate. It covers the transition from the 3.75 mg/23 mg starting dose directly to the highest claimed maintenance strength.
Qsymia’s labeled dose escalation normally includes an intermediate 7.5 mg/46 mg strength and, where clinically appropriate, escalation to 11.25 mg/69 mg before the 15 mg/92 mg dose. The patent claims do not expressly require that every intermediate strength be administered. A protocol that includes intermediate titration could still implicate claim 18 if it also satisfies the first-dose and final-dose limitations.
What formulations are protected by US 8,895,057?
The patent requires a dual-release dosage form:
- Phentermine must be formulated for immediate release.
- Topiramate must be formulated for controlled release.
- The controlled-release topiramate must delay and reduce peak exposure while preserving AUC.
Dependent claim 15 expressly identifies sustained release, delayed release, or both. Claim 16 specifies oral administration.
The formulation limitation is central. A conventional immediate-release tablet containing both ingredients would not satisfy the controlled-release topiramate limitation. Conversely, a formulation using extended-release phentermine but immediate-release topiramate would not satisfy the claimed release architecture.
Pharmacokinetic limitation
The pharmacokinetic language is unusually important. The claim requires controlled-release topiramate to:
- Reach Cmax at approximately 6 to 10 hours after administration.
- Have a lower Cmax than non-controlled-release topiramate.
- Preserve total exposure, measured by AUC.
Claim 14 narrows the requirement by specifying a Tmax delay of approximately 6 to 8 hours compared with non-controlled-release topiramate.
These limitations create both a technical barrier and a potential litigation issue. A generic developer could attempt to design around the patent by using a release profile that does not meet the specified Tmax range, although the product would still need to satisfy FDA bioequivalence requirements for the reference product.
How do the dependent claims expand coverage?
Claims 2 through 17 depend from claim 1. Claims 19 through 33 depend from claim 18.
The dependent claims add four principal categories of limitations:
| Category |
Examples |
| Patient population |
BMI 25 to 29.9 kg/m²; BMI of at least 30 kg/m² |
| Obesity-related conditions |
Diabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease |
| Salt equivalence |
4.92 mg phentermine hydrochloride corresponding to 3.75 mg phentermine; 9.84 mg corresponding to 7.5 mg phentermine |
| Clinical result |
At least 10% body-weight reduction |
Claims 6, 7, 23, and 24 list a wide range of obesity-associated diseases. Claims 8 through 11 and 25 through 28 narrow the disease group to high blood pressure, elevated triglycerides, elevated fasting glucose, and diabetes, including combinations of at least two conditions.
These dependent claims may have limited practical value if the independent claim is already satisfied by the ordinary labeled use of the product. They can still provide fallback positions in litigation if a court limits the construction of the broader independent claims.
When does US Patent 8,895,057 expire?
US 8,895,057 was issued on November 25, 2014. Public patent records identify a priority chain associated with the development of controlled-release topiramate and phentermine, with a nominal patent-term endpoint in May 2027.[1]
The patent term must be distinguished from FDA regulatory exclusivity. Patent expiration is determined under 35 U.S.C. § 154 and the applicable continuation and priority rules. FDA marketing exclusivity is governed separately under the Federal Food, Drug, and Cosmetic Act.
| Milestone |
Date |
| Patent issued |
November 25, 2014 |
| Nominal statutory endpoint |
May 2027 |
| Product associated with patent |
Qsymia |
| FDA application |
NDA 022580 |
| FDA approval of Qsymia |
July 17, 2012 |
The patent is not a biologic patent and does not create biosimilar exclusivity. It is relevant to abbreviated new drug applications, or ANDAs, for generic phentermine/topiramate products.
What is the Orange Book status of Qsymia-related patents?
FDA Orange Book listings for Qsymia have included patents directed to the combination, formulation, and methods of use. The Orange Book is the controlling public FDA source for listed patents and expiration information, while the patent document itself controls claim language.[2]
Relevant Qsymia patent categories include:
| Patent category |
Commercial significance |
| Combination patents |
Cover the use or composition of phentermine and topiramate together |
| Controlled-release formulation patents |
Protect release characteristics and dosage-form architecture |
| Method-of-use patents |
Cover treatment of obesity and associated metabolic conditions |
| Dosing-regimen patents |
Cover titration and maintenance schedules |
US 8,895,057 should be analyzed with the complete Orange Book listing for NDA 022580. A patent may remain enforceable even if it is not listed in the Orange Book, but an unlisted method-of-use patent generally has a different ANDA litigation posture from a listed patent.
What FDA regulatory status applies to Qsymia?
Qsymia was approved by FDA in 2012 as an extended-release oral capsule containing phentermine hydrochloride and topiramate.[3] The approved strengths are:
| Qsymia strength |
Phentermine HCl |
Topiramate |
| Initial |
3.75 mg |
23 mg |
| Low maintenance |
7.5 mg |
46 mg |
| Intermediate |
11.25 mg |
69 mg |
| High maintenance |
15 mg |
92 mg |
The label directs initial treatment with 3.75 mg/23 mg, followed by 7.5 mg/46 mg. Patients with inadequate weight loss may be escalated to the higher dose after additional evaluation.[3]
The labeled use closely corresponds to the dosing structure in US 8,895,057. The patent’s two-year administration requirement is less likely to be expressly stated in an ordinary prescription instruction, but a patient who follows long-term Qsymia therapy could satisfy that limitation.
Qsymia is subject to safety controls associated with phentermine, teratogenic risk from topiramate, psychiatric effects, metabolic acidosis, increased heart rate, and potential ocular adverse events. Regulatory compliance does not determine patent infringement, but the approved label is relevant to induced-infringement theories and to the practical scope of method claims.
Which companies are challenging Qsymia patent protection?
A definitive Paragraph IV analysis requires the current Orange Book and FDA Paragraph IV notices for NDA 022580, together with ANDA litigation records. The claim text alone does not establish whether a specific generic company has filed an ANDA, whether a notice was served, or whether litigation has settled.
For a generic applicant, the principal challenge paths would be:
- Paragraph IV certification that the listed patent is invalid, unenforceable, or not infringed.
- Paragraph III certification accepting delayed approval until patent expiration.
- A section viii statement carving out patented methods of use, where the remaining label supports approval.
- A formulation design that avoids the claimed controlled-release pharmacokinetic profile.
Because claims 1 and 18 are method claims, a generic applicant may attempt to omit or narrow directions corresponding to the patented titration regimen. That strategy is constrained if the proposed product’s FDA labeling still instructs the same dose escalation.
What generic launch risks exist for Qsymia?
The most realistic launch scenarios are:
Launch after patent expiry
A generic can launch after all blocking patents expire or after an agreed licensed entry date. This is the lowest litigation-risk pathway but may result in substantial price erosion once several manufacturers enter.
Paragraph IV litigation and 30-month stay
A Paragraph IV notice can trigger patent litigation. Under the Hatch-Waxman framework, timely litigation by the NDA holder can result in a statutory stay of FDA approval, generally up to 30 months, subject to statutory exceptions and court action.[4]
Carve-out launch
A generic may seek approval with a section viii labeling carve-out for patented indications or dosing instructions. This approach is difficult where the patented regimen is closely integrated into the product’s principal obesity indication.
At-risk launch
A generic may launch before final resolution of patent litigation. This exposes the applicant to damages, injunctive relief, and potential enhanced damages if the patent is found valid and infringed.
How strong is the patent estate for Qsymia?
US 8,895,057 has meaningful commercial relevance but a narrower enforceability profile than a composition-of-matter patent.
Strengths
- It maps closely to Qsymia’s approved strengths and titration sequence.
- It combines dose, release profile, pharmacokinetic, patient, and duration limitations.
- The claims cover both the 7.5 mg/46 mg and 15 mg/92 mg maintenance pathways.
- Controlled-release topiramate creates a formulation and pharmacokinetic barrier.
Vulnerabilities
- The claims require long-term administration for at least two years.
- “About” ranges for Tmax and dose equivalence may create claim-construction disputes.
- The Cmax and AUC limitations may require extensive pharmacokinetic evidence.
- Method claims are vulnerable to treatment-protocol design-arounds.
- The patent does not broadly preclude all generic combinations of phentermine and topiramate.
- The disease lists in the dependent claims are broad and may raise written-description or enablement issues for some listed conditions.
The strongest enforcement case would involve a generic label that reproduces Qsymia’s titration instructions and a product that demonstrably produces the claimed controlled-release topiramate profile.
What patent litigation affects Qsymia?
The principal litigation question is whether an ANDA applicant’s proposed label and product satisfy every limitation of claims 1 or 18. A patent holder would need to establish, among other points:
- The proposed product contains the claimed quantities of active ingredients.
- Phentermine is immediate release.
- Topiramate is controlled release.
- The topiramate Tmax falls within the claimed range.
- Cmax is reduced relative to non-controlled-release topiramate.
- AUC is not reduced.
- The proposed labeling induces administration for the claimed periods.
A generic defendant could contest infringement by arguing that its product does not meet the pharmacokinetic limitations, that the label does not require two years of treatment, or that the claims are invalid for anticipation, obviousness, indefiniteness, written-description failure, or lack of enablement.
How does US 8,895,057 compare with competing obesity-drug patents?
US 8,895,057 differs materially from patents covering GLP-1 agonists such as semaglutide or liraglutide.
| Attribute |
US 8,895,057 |
GLP-1 agonist patent estates |
| Active ingredients |
Small-molecule phentermine and topiramate |
Peptide agonists |
| Primary protection |
Regimen and controlled-release formulation |
Composition, sequence, formulation, device, and manufacturing |
| Regulatory pathway |
ANDA |
Often biologics or complex-drug pathways, depending on product |
| Biosimilar relevance |
None |
Potentially significant |
| Main design-around route |
Alter dose sequence or release profile |
Alternative sequence, formulation, device, or manufacturing process |
| Main commercial risk |
Generic small-molecule entry |
Layered patent and device challenges |
Qsymia’s estate is more exposed to conventional generic competition than a peptide-based obesity product with extensive composition and device protection. Its commercial defense depends heavily on formulation patents, label strategy, and any settlement terms with generic applicants.
What licensing deals and settlements matter?
The claims and patent number do not identify licensing agreements or settlement terms. No licensing right, authorized-generic arrangement, or generic-entry date should be inferred from the patent document.
Where a Paragraph IV settlement exists, the commercially relevant terms usually include:
- The agreed generic launch date.
- Whether the launch is exclusive or nonexclusive.
- Authorized-generic rights.
- Royalty obligations.
- Restrictions on dosage strengths or indications.
- Covenants concerning future patents.
- Acceleration provisions if the patent is invalidated.
These terms can materially change the practical exclusivity period without changing the patent’s statutory expiration date.
What manufacturing and intellectual-property barriers remain?
The primary technical barrier is reproducing the claimed release relationship between topiramate and phentermine. A developer must address:
- Controlled-release topiramate particle or matrix technology.
- Immediate-release phentermine delivery within the same oral dosage form.
- Dose uniformity across multiple strengths.
- Comparable pharmacokinetic exposure.
- Stability and dissolution performance.
- FDA bioequivalence requirements.
- Labeling that avoids unnecessary patented method instructions.
Manufacturing know-how may provide commercial protection even where the patent claims are successfully designed around. That protection is weaker than patent protection because it depends on secrecy, process complexity, and regulatory reproducibility.
Key Takeaways
- US 8,895,057 is a method-of-use patent for staged phentermine/topiramate therapy.
- Its core coverage is the 3.75 mg/23 mg starting dose followed by either 7.5 mg/46 mg or 15 mg/92 mg.
- The patent requires controlled-release topiramate with delayed Tmax, reduced Cmax, and preserved AUC.
- The two-year maintenance limitation materially narrows the claims.
- Qsymia is the principal commercial product aligned with the claimed regimen.
- The patent’s nominal expiration is in May 2027.
- The patent does not create biosimilar exclusivity because Qsymia is a small-molecule product.
- Generic risk will turn on the complete Orange Book listing, Paragraph IV certifications, ANDA labeling, formulation data, and any settlement agreements.
- The patent is stronger against a generic that copies the Qsymia label and release profile than against a product using a materially different regimen or formulation.
FAQs
Can a generic avoid US 8,895,057 by using only the 7.5 mg/46 mg strength?
Not necessarily. Claim 1 specifically covers escalation from 3.75 mg/23 mg to 7.5 mg/46 mg. A generic using that sequence could still face infringement allegations if its formulation and pharmacokinetic profile satisfy the remaining limitations.
Does the patent cover phentermine alone or topiramate alone?
No. The independent claims require a combined dosage regimen containing both phentermine and topiramate.
Does a patient need to lose at least 10% of body weight to infringe claim 1?
No. The 10% reduction is a limitation only in dependent claims 17 and 33. Claims 1 and 18 require that the regimen effect weight loss but do not expressly require a 10% reduction.
Can a physician’s off-label prescription infringe the patent?
Potentially. Method-of-treatment infringement depends on whether the claimed steps are performed or induced, not solely on whether the use is FDA-approved. The specific facts of the prescription, product, instructions, and administration would control.
Does expiration of US 8,895,057 automatically permit generic Qsymia launch?
No. Other listed or unlisted patents, regulatory requirements, court orders, settlement agreements, and exclusivity periods may independently delay or restrict launch.
References
- United States Patent and Trademark Office. (2014). US Patent No. 8,895,057, methods of treating obesity using controlled release topiramate and phentermine.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Qsymia prescribing information, NDA 022580.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355 and 35 U.S.C. § 271(e).
